BioCardia (BCDA) Financials: Revenue & Earnings
BCDA$0.93-0.02 -2.35%
$14.00M
Market Cap
-1.21
P/E
—
Forward P/E
51
Score
BioCardia (BCDA) Financials: Revenue & Earnings
BCDA price $0.93 -0.02 -2.35%
- Ticker
- BCDA
- Price
- $0.93
- Change
- -0.02 -2.35%
- Market cap ?
- $14.00M
- P/E ?
- -1.21
- Dividend yield ?
- 0.00%
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 51
- Value
- 58
- Quality
- 46
- Growth
- 50
Stocklytics score rationale: value 58, quality 46, growth 50.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 576000 | 479000 | 625000 | 710000 | 145000 | 1015000 | 1352000 | 477000 | 58000 | 0 |
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program…
Earnings and financials
BioCardia, Inc. (BCDA) trades at $0.93, with a market cap of $14.00M and a trailing P/E of -1.21. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 576000 | 479000 | 625000 | 710000 | 145000 | 1015000 | 1352000 | 477000 | 58000 | 0 |
Insights · Dividends · Forecast · Financials · Learn